What is Zacks Research’s Forecast for Chemours Q1 Earnings?

The Chemours Company (NYSE:CC) – Stock analysts at Zacks Research decreased their Q1 2027 earnings per share estimates for shares of Chemours in a research note issued to investors on Wednesday, July 22nd. Zacks Research analyst Team now expects that the specialty chemicals company will post earnings per share of $0.39 for the quarter, down from their prior forecast of $0.41. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $1.18 per share. Zacks Research also issued estimates for Chemours’ Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.10. Chemours had a positive return on equity of 52.49% and a negative net margin of 6.82%.The business had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the previous year, the business earned $0.13 EPS. The company’s revenue for the quarter was up 1.0% on a year-over-year basis.

Several other equities research analysts have also issued reports on the stock. Truist Financial increased their price objective on shares of Chemours from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. UBS Group lifted their target price on shares of Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a report on Friday, May 8th. Alembic Global Advisors reaffirmed an “overweight” rating and set a $30.00 price target on shares of Chemours in a research report on Wednesday, May 13th. Mizuho lowered their price target on Chemours from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. boosted their price objective on Chemours from $17.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.10.

Chemours Trading Down 1.3%

Shares of CC stock opened at $17.25 on Thursday. The stock has a market cap of $2.59 billion, a price-to-earnings ratio of -6.53 and a beta of 1.41. The company has a quick ratio of 0.87, a current ratio of 1.82 and a debt-to-equity ratio of 18.98. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The firm’s 50 day moving average price is $20.35 and its two-hundred day moving average price is $19.87.

Hedge Funds Weigh In On Chemours

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in shares of Chemours by 79.1% in the first quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock worth $29,014,000 after buying an additional 581,621 shares during the last quarter. Edgestream Partners L.P. raised its holdings in Chemours by 1,126.4% in the first quarter. Edgestream Partners L.P. now owns 294,881 shares of the specialty chemicals company’s stock valued at $6,496,000 after acquiring an additional 270,836 shares in the last quarter. Amundi bought a new position in Chemours during the 1st quarter valued at $272,000. California State Teachers Retirement System boosted its stake in Chemours by 18.8% during the 1st quarter. California State Teachers Retirement System now owns 173,103 shares of the specialty chemicals company’s stock valued at $3,813,000 after acquiring an additional 27,377 shares during the last quarter. Finally, Quantinno Capital Management LP grew its holdings in Chemours by 16.4% during the 1st quarter. Quantinno Capital Management LP now owns 364,745 shares of the specialty chemicals company’s stock worth $8,035,000 after acquiring an additional 51,275 shares in the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend was Friday, May 15th. Chemours’s dividend payout ratio is presently -13.26%.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade
• Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time.
• Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance.
• Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call
• Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.